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ABSTRACT

M ICROVASCULAR ENDOTHELIAL CELLS OF THE BOVINE CORPUS
LUTEUM: A COMPARATIVE STUDY OF THE ESTROUS CYCLE AND
PREGNANCY

by
Jessica A. Cherry
University of New Hampshire, September, 2006

Endothelial cells derived from the corpus luteum (CLENDOs) exhibit a diverse
array of characteristics that seemingly complement their wide-ranging properties
in luteal function and fate. Reproductive status of the animal (i.e., non-pregnant
vs. pregnant) may contribute to the phenotypic/physiologic diversity of
microvascular endothelial cells, but information in this regard is limited. Here,
structural and functional attributes of CLENDOs derived from the estrous cycle
(Days 9-12) were compared with those of pregnancy (Day 60). Initially, lectin
binding properties were examined in the cells. Using fluorescent-tagged lectins
for Bandeiraea simplicifolia I or concanavalin A, flow cytometric analysis
indicated that lectin-binding on CLENDOs of the estrous cycle did not differ from
those of pregnancy (P > 0.05). Next, the CLENDOs were exposed to tumor
necrosis factor alpha (TNF; 50 ng/ml) and/or interferon gamma (IFNG; 30 ng/ml)
to assess cytokine-induced intracellular signaling [inhibitor kappa B alpha (HcBa)
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degradation and induction of interferon regulatory factor 1 (IRF-1)], production of
cytokines [TNF and monocyte chemoattractant protein 1 (CCL2)], and cell death.
Western blot analysis revealed that both types of CLENDOs exhibited a rapid
decrease in k B a (P < 0.05), and an equally rapid increase in IRF-1 (P < 0.05), in
response to cytokine treatment that was not influenced by reproductive status (P
> 0.05). IFNG stimulated production of TNF by the CLENDOs (P < 0.05),
revealing that CLENDOs are a source of TNF, regardless of reproductive status
(P > 0.05). Based on these findings, the ability of TNF to mediate IFNG-induced
effects was assessed using etanercept, a TNF antagonist. Etanercept inhibited
direct actions of TNF with respect to CCL2 secretion and IRF-1 induction (P <
0.05), but did not alter IFNG effects (P > 0.05). Lastly, we determined by
measuring the incidence of cell death that CLENDOs of the estrous cycle are
similarly susceptible to TNF- and TN F + IFNG-induced death as CLENDOs of
pregnancy. These results indicate that several attributes of CLENDOs from the
estrous cycle are retained by those of early pregnancy, including lectin binding
properties, activation of specific cytokine-initiated intracellular signals, and the
instigation of cytokine-induced inflammatory events.

IX

R eproduced with perm ission o f the copyright owner. F urther reproduction prohibited w itho ut perm ission.

CHAPTER I

LITERATURE REVIEW

Introduction
As the world’s population exceeds 6.5 billion people, with estimates
reaching 10 billion by the year 2050, the demand for food products grows ever
greater [1]. In 2005, the estimated world consumption of beef and dairy products
based upon some of the most populous countries (China, European Union, India,
Russia, and the United States) was 50,000 metric tons and 85,000 metric tons,
respectively [2, 3]. From this perspective, it would seem essential to increase
reproductive rates in cattle to meet growing demands for beef and dairy products.
Unfortunately, fertility rates are currently abysmal in cattle. Conception rates in
lactating cows are approximately 35-45% [4], Embryo mortality rates stand at
30-40% [5]. One of the most important aspects of early pregnancy is the
development and maintenance of a functional corpus luteum (CL), a structure
within the ovary that secretes the ‘hormone of pregnancy’, progesterone.
Understanding the cellular and molecular characteristics of CL formation,
function, and regression within the estrous cycle and throughout pregnancy are
key components to improving fertility in cattle, thus optimizing beef and dairy
production to feed the growing world population.
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Estrous Cycle
The bovine estrous cycle is approximately 21 days and is dominated and
controlled by the CL. The estrous cycle is characterized by four distinct phases:
estrus, metestrus, diestrus, and proestrus. Estrus is the phase during which the
cow is sexually receptive to the bull. More importantly, it is at the end of this
phase that ovulation or the release of the oocyte for fertilization occurs [6]. The
mature, tertiary, or Graafian follicle is the structure that contains the oocyte. The
follicle is a fluid-filled structure consisting primarily of two cell types, theca and
granulosa cells [7], The main function of the follicle, along with supporting the
growth and maturation of the oocyte, is to produce estradiol. Estradiol is
produced through the joint efforts of both the theca and granulosa cells, which
carry out this process in what is known as the two-cell theory of estradiol
production [8, 9]. Theca cells compose the outside of the follicle (theca externa)
and contain the vasculature (theca interna). Granulosa cells constitute the inside
cavity of the follicle and are separated from the theca cells and vasculature by a
basement membrane [7]. Granulosa cells also form a mass surrounding the
oocyte called the cumulus oophorus, which anchors it to the granulosa cell layer
within the follicle [10]. As ovulation occurs (approximately 10 hours after the end
of estrus - day 0), the oocyte is expelled from the follicle and travels into the
oviduct to await fertilization [6]. With ovulation, the basement membrane
separating the theca and granulosa layers of the follicle begins to disintegrate.
This leads to an invasion of capillaries and new vessel formation extending from
the theca intema [11]. Also, under the stimulation of luteinizing hormone (LH),
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theca and granulosa cells undergo a process known as luteinization, in which the
cells transform into small and large luteal cells, respectively [12]. As a result of
all these events, the remnants of the follicle transform into a different structure,
both physically and functionally, the CL [6, 7].
At the conclusion of estrus, metestrus begins (days 1-4). This phase is
characterized by the beginning of CL dominance and relatively low circulating
levels of progesterone and estradiol. It is during this time that the CL matures
and gradually increases its progesterone production. Estradiol production stems
from an initial wave of follicle development, but these follicles eventually die by
atresia due to the prevailing concentrations of progesterone present [6].
The next 10-15 days of the estrous cycle are described as the diestrus
phase (days 5-18) and can be thought of as the classic period of the luteal phase
when progesterone production is at its maximum. During diestrus, a second
wave of follicular development may occur, but the follicles quickly meet the same
atretic fate as those of the first wave. At approximately day 17, the CL
undergoes the process of luteal regression if pregnancy does not occur. This is
classically characterized and attributed to the uterine release of the luteolytic
agent prostaglandin F2a (P G F2a) [6],
Once the process of luteal regression is initiated, proestrus begins (days
18-20). At this time, a final wave of follicular growth occurs, which eventually
results in the dominance of a Graafian ovulatory follicle due to declining
concentrations of progesterone. Concomitantly, increasing estradiol from the
dominant follicle signals to the hypothalamus and pituitary gland in the brain.

3
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This triggers increased gonadotropin releasing hormone (GnRH) secretion, which
leads to a release of LH and follicle stimulating hormone (FSH). A surge in LH
secretion occurs approximately 12 hours after the peak in estradiol. Together,
these effects result in the onset of estrus, ovulation (10 hours after the end of
estrus), and the commencement of CL formation, function, and regression for the
subsequent estrous cycle [6].

Corpus Luteum
The CL is a transient endocrine tissue that forms within the ovary from the
remnants of the ovulated follicle. The primary responsibility of the CL is to
maintain pregnancy, which was first described by Frankel in 1903 who
discovered that removal of the CL resulted in abortion in rabbits [1 3,14]. At the
time, Frankel did not know the identity or nature of the substance responsible for
maintaining pregnancy. However, 30 years later Allen and Corner described an
extract from the CL that maintained the pregnancy of ovariectomized rabbits [14,
15]. The component isolated, subsequently called progesterone, was crystallized
by Allen and Wintersteiner in 1934 [14,16].
Progesterone is a steroid produced and secreted by the CL. It is primarily
the ‘hormone of pregnancy’ that influences uterine function, but also has other
biological targets and effects. Working in concert with estradiol, progesterone
prepares the genital tract, uterus, and cervix to establish and sustain a
pregnancy. Progesterone affects the mucosal lining of the genital tract,
influencing the transport of the oocyte or fertilized ovum in the oviduct, prepares
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the uterus for implantation of the embryo and subsequent pregnancy, and
increases the viscosity of cervical mucus, thereby providing a barrier between the
uterus and the outside environment [14].
The CL consists primarily of four distinct cell types: large steroidogenic
cells, small steroidogenic cells, endothelial cells, and fibroblasts. Steroidogenic
cells make up approximately 30% of the tissue, while the most abundant cell type
of the CL is the endothelial cell population, comprising approximately 50% of the
midcycle tissue. Lastly, fibroblasts constitute approximately 10% of the total cell
population, with immune cells and other unidentified cell types encompassing the
remaining 10% [17].
As evidenced from the total numbers of endothelial cells, the CL is a
highly vascularized tissue. The tissue is characterized by having a relatively high
rate of blood flow (-3 0 mL/min x g of tissue) compared to other tissues (e.g. - 3
mL/min x g of tissue for the adrenal gland). Also, 65-95% of total ovarian blood
flow is directed toward the CL during the midcycle phase [18]. The dense
capillary network constitutes the communication system between the CL and the
rest of the body; delivering hormones, nutrients, and substrates for steroidogenic
capacity, and distributing progesterone to its target tissues [18,19], The
vasculature is essential for the formation, maintenance, and regression of the CL,
with the opposing processes of angiogenesis and angioregression, respectively,
in the forefront.

5
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Angiogenesis and Corpus Luteum Formation
Angiogenesis is defined as the generation of new blood vessels through
the sprouting (migration and proliferation) of existing blood vessels [20].
Endothelial cells are mainly responsible for angiogenesis. They must initiate a
morphogenetic cascade in which extracellular matrix is degraded and in which
cells migrate toward an angiogenic stimulus, proliferate, and organize into a
network of new capillaries [21]. The process of angiogenesis occurs rarely in
adults. It is primarily restricted to pathological conditions such as tumor growth
and metastasis, and physiological conditions such as wound healing,
inflammation, and processes pertaining to the female reproductive system (e.g.,
placentation) [22-24].
In the female reproductive system, angiogenesis occurs in the uterus and
placenta during pregnancy, in addition to the mammary glands. Also, a
hormonally-regulated, cyclic form of angiogenesis occurs in the uterus and
ovaries throughout each estrous cycle [20]. In particular, the angiogenic process
in the ovary is of paramount importance to angiogenesis during the formation of
the CL. The relatively brief lifespan of the CL provides a useful model for
understanding the natural angiogenic life cycle (formation, maintenance, and
regression), important not only for reproduction, but also in terms of
understanding angiogenesis in tumor growth and regression [24].
Angiogenesis in the ovary is primarily controlled by angiogenic factors
such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor
(bFGF), and angiopoeitins (Ang 1 and Ang 2). VEG F affects vasodilation,
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capillary permeability, and stimulates endothelial cell proliferation. The first
angiogenic cytokine identified in the ovary was bFGF [25], which is a potent
endothelial cell mitogen. Ang 1 and Ang 2 are important growth factors in the
formation of new blood vessels [23, 26].
The angiogenic process in the follicle precedes angiogenesis in the CL, or
luteal angiogenesis. Ovarian follicles consist primarily of four stages of growth:
primordial, primary, secondary, and tertiary or Graafian. Primordial and primary
follicles generally have no vascular network of their own and therefore are not
associated with any aspects of angiogenesis. As follicles develop an antrum
(secondary and Graafian follicles), a capillary network is established. There is a
direct connection between growth and differentiation of these follicles and an
increased density of blood vessels within the theca cell layers. The vascular
network is restricted to the theca interna and does not penetrate the basement
membrane into the granulosa cell layers. The granulosa layers of the Graafian
follicle, therefore, are avascular. Nutrients and metabolites, including hormones,
are exchanged via diffusion [19, 23, 24].
At ovulation, the basement membrane separating the granulosa and theca
layers disintegrates, permitting the invasion of migrating endothelial cells. This
process, called luteinization, is partially dependent upon angiogenesis. The CL
undergoes massive growth in a matter of days and is accompanied by an equally
massive neovascularization. In sheep, for example, new vessel formation in the
CL is detected within 36 hours of ovulation [27] and more than 50% of the
proliferating cells in the vascular compartment are endothelial cells [28]. The rich
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vascular network of the CL is established to support the dynamic endocrine
function of the gland [23, 24]. Inadequate vascular formation may play a role in
ovarian cystic diseases and reduced luteal function [23].

Corpus Luteum Maintenance
The maintenance of the vasculature is of major importance to the midcycle
CL. Rate of endothelial cell proliferation decreases at this time compared to the
forming CL, but there is still extensive angiogenesis [23, 29]. Steroidogenic
capacity of the CL is at a maximum, with the vasculature maintaining an intimate
relationship with the steroidogenic cells to ensure progesterone synthesis and
secretion. In fact, each steroidogenic cell is in direct contact with at least two or
more neighboring capillaries during this period of time [24],

Angioregression and Corpus Luteum Regression
At the onset of luteal regression, a decline in serum progesterone begins,
followed by a rapid decrease in luteal weight [30]. This rapid loss of tissue is
accompanied by a reduction of blood flow and loss of vasculature, a process
known as angioregression, which results in the sharp decrease in numbers of
endothelial cells. Angioregression is a process usually associated with tissue
involution, such as scar formation during wound healing. According to Modlich et
al. (1996) [21], there are two putative mechanisms by which angioregression
occurs in the CL of the estrous cycle. The first is the loss of endothelial cell tight
junctions and subsequent detachment of cells from the basement membrane of
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the microvasculature. In the guinea pig, early signs of endothelial cell
degeneration within the CL include loss of tight junctions, protrusion of cells into
the capillary lumen, and formation of adherens junctions with endothelial cells on
the opposite side of the lumen [31]. Following detachment of the endothelial
cells, apoptosis and subsequent removal of the apoptotic bodies from the
circulation occurs. The second mechanism of angioregression is characterized
by contraction and occlusion of arterioles and small arteries through proliferation
of smooth muscle cells surrounding the vessels. Little is known about the
endocrine events that lead to this mechanism of regression, but vessel occlusion
suggests that contraction and limited perfusion of the CL may predispose it to
endothelial cell detachment and deletion [21].
Another aspect of luteal regression is the role of the uterus. The uterus
has a prominent role in regulating the lifespan of the CL and initiating the process
of luteal regression in most mammals. Hysterectomy prolongs the lifespan of the
CL in the cow [32], and luteal structure and function are normally maintained for
the duration of a pregnancy after removal of the uterus [33]. PGF2a is the
hormone from the uterus that influences luteal lifespan [34]. Endometrial tissue
concentrations of PGF 2 a are maximal during luteal regression. But the strongest
evidence that PGF2a is involved in luteal regression stems from the fact that
treating animals with prostaglandin synthesis inhibitors, such as indomethacin,
blocks spontaneous luteal regression [14]. Also, immunizing cattle to PGF2ot
prevents spontaneous luteal regression [14]. The luteolytic actions of PGF2a
differ among species and between in vivo and in vitro models. Proposed
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mechanisms of PGF2a action include a large and rapid decline in luteal blood flow
due to its vasoconstrictive effects, reduced LH receptor expression, and direct
cytotoxic effects, to name a few [14].
Although the role of PGF2a in luteal regression is important, it cannot
account for all aspects of luteal regression. For instance, PGF2(X in vitro does not
inhibit basal progesterone production by steroidogenic luteal cells, leading one to
believe that other cell types or substances contribute to luteal regression [35],
One widely-recognized aspect of luteal regression in most species is the
accumulation of immune cells and the onset of immune-mediated events that
degrade tissue. At the time of luteal regression, T lymphocytes and
macrophages increase in the CL of the bovine [36, 37], equine [38], murine [39],
leporine [40], porcine [41], and human [42, 43]. An increase in major
histocompatibility complex (M HC) class II expression on bovine [44], ovine [45],
and human [42] steroidogenic cells also suggests immune-mediated
mechanisms are in place. T lymphocytes and macrophages are important in the
production of cytokines, and MHC class II molecule expression is essential to
activating and targeting the immune response.
Activated T lymphocytes and macrophages in the CL produce cytokines,
particularly interferon gamma (IFNG ) and tumor necrosis factor alpha (TNF),
respectively. IFNG and TNF mRNA expression is detectable in the CL
throughout the estrous cycle, with TN F levels rising slightly during luteal
regression [46]. The properties of IFNG and TNF will be discussed further in
later sections, but in terms of luteal regression, they are anti-steroidogenic,

10

R eproduced with perm ission o f the copyright owner. F urther reproduction prohibited w itho ut perm ission.

apoptotic, and increase the expression of MHC molecules in steroidogenic luteal
cells [47].
Another immunological component of luteal regression is the attraction
and recruitment of immune cells through chemokines, which facilitate adhesion,
activation, and chemotaxis of leukocytes. Of particular interest is monocyte
chemoattractant protein 1 or chemokine ligand 2 (CCL2), a chemokine produced
by endothelial cells of the CL [48], and known for its recruitment of monocytes,
basophils, natural killer cells, and T lymphocytes [49]. CCL2 expression has
been documented in the bovine [50, 51], murine [39, 52], and ovine [53, 54] CL.
In the bovine CL, CCL2 expression (mRNA and protein) increases during the
latter half of the estrous cycle (days 12-18) and is accompanied by an
accumulation of immune cells, indicating CCL2 has a role in immune cell
recruitment prior to and during luteal regression [51].
Another molecule implicated in luteal regression is the vasoconstrictive
peptide, endothelin 1 (EDN1). EDN1 is a 21-amino acid peptide produced and
secreted by endothelial cells [55]. It temporarily inhibits progesterone production
by the CL in the murine [56], ovine [57, 58], bovine [55], and human [59]. EDN1
has become a major focus in luteal regression based on its potential role in
PGF2a-induced luteal regression. During the early luteal phase, when the CL
does not respond to PGF 2 a, EDN1 has no effect on progesterone secretion [60].
But, during the midcycle and late cycle CL, administration of PGF2a in
conjunction with EDN1 results in reduced plasma progesterone concentrations,
which are reversed by an EDN1 antagonist [55, 58, 61]. These results indicate
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that EDN1 mediates luteolytic effects of PGF2a from a functional standpoint [62].
However, there is no documentation that EDN1 alters the structural integrity of
the CL [63],
Collectively, vasoactive peptides, such as PGF2a and EDN1, and
components of the immune system, including T lymphocytes, macrophages,
cytokines, and chemokines, contribute to luteal regression. Further study is
required to fully elucidate the signals affecting endothelial cell function within the
CL during angioregression and subsequent luteal regression.

Corpus Luteum of Pregnancy
Gestation length for a cow is approximately 280 days. The CL is required
to maintain the pregnancy for the first 200 days, as removal of the CL before this
time results in termination of the pregnancy [64]. In the ovine CL, the
morphological characteristics of steroidogenic cells of pregnancy are similar to
those of the midcycle CL. The ability of steroidogenic cells to produce
progesterone is maintained, but declines slowly as gestation progresses. Signs
of cell death in isolated areas appear shortly before parturition. The structural
and functional changes observed in the CL of pregnancy during regression are
similar to those of the estrous cycle, with the exception that elimination of dead
and dying cells occurs over a longer period of time [65].
Mechanistically, the maintenance of the CL of pregnancy is not fully
understood. Maternal recognition of pregnancy through the secretion of
interferon tau and inhibition of uterine PGF2a secretion are among the
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mechanisms which must occur in order to maintain pregnancy [14]. In cattle,
luteolytic effects of PGF2a are blocked by an endometrial prostaglandin inhibitor
or a factor produced by the embryo, bovine trophoblast protein-1 complex, also
known as embryonic interferon or interferon tau [30, 66, 67]. Additionally,
preventing an influx of immune cells and the actions of cytokines within the CL of
early pregnancy appear to be essential. High concentrations of progesterone are
immunosuppressive and inhibit lymphocyte proliferation and function [47] and
MHC expression on luteal cells [68], Nevertheless, in-depth knowledge of the
signals and intracellular mechanisms involved in maternal recognition of
pregnancy and the maintenance of the CL during pregnancy are not fully
understood and therefore require further study.

Endothelial Cells of the Bovine Corpus Luteum
Endothelial cells composing the microvasculature of the bovine CL play a
significant role in the formation, function, and regression of the CL. Angiogenesis
is essential to the development of the gland; an extensive vascular network must
be formed in order for the tissue to survive, as an inadequate vasculature is
associated with reduced luteal function [23]. Maintenance and stability of the
vasculature is paramount to the endocrine function of the gland, importing
nutrients, substrates, and hormones, and exporting progesterone to its target
tissues [18]. The endothelial cell component of the CL is the first to undergo cell
death during luteal regression, thereby eliminating the blood supply to the tissue
and dictating its fate [31], The CL is a transient gland, but it is also one of the
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most highly vascularized tissues in the body, with endothelial cells composing
approximately 50% of the total number of cells [17], Given the crucial roles of
endothelial cells within the CL, it is important to understand them from both
morphologic and physiologic standpoints.
There are four distinct types of microvascular endothelial cells of the
bovine corpus luteum (CLENDOs). Originally, five types were characterized, but
the fifth was later attributed to be of immature granulosa cell origin, secreting
progesterone and being unresponsive to LH stimulation [69], The remaining four
types of CLENDOs are characterized based upon morphology, function, surface
molecule expression, and cytokeratin 8, 9, and 18 expression [70-75]. All cell
types maintain contact-inhibited growth and unique morphologic characteristics in
long-term cultures. Also, all express angiotensin converting enzyme (ACE) and
internalize acetylated low-density lipoprotein (acLDL), which are hallmarks of
endothelial cells [70].
Type 1 CLENDOs are isomorphic cells having a cobblestone appearance
in confluent cultures [70]. They express factor Vlll-related antigen and ACE, both
of which are localized to the perinuclear area, and they exhibit moderate uptake
of acLDL. The surface of type 1 cells contains many microvilli and globular
protrusions in the central area of the apical side of the cell. They also express
two families of adhesion molecules, neuronal cell adhesion molecule (NCAM140) and epithelial cadherin (E-CAD). These cells stain positively for cytokeratin
18 (CK18) [71, 74],
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Type 2 CLENDOs are polymorphic cells with numerous nuclei and lacking
prominent cobblestone morphology [70], They are similar to type 1 cells in that
they express factor Vlll-related antigen and ACE, and exhibit moderate acLDL
uptake. Similar to type 1 cells, type 2 cells are NCAM-140 positive, but do not
express CAD molecules. These cells are also CK18 positive [71, 74].
Type 3 CLENDOs are spindle-shaped cells containing at least one
prominent intracellular vacuole [70], They have a smooth cell surface with
processes at the poles, and express factor Vlll-related antigen and ACE
throughout the cytoplasm. Unlike type 1 and 2 CLENDOs, type 3 cells readily
uptake acLDL and store it in lysosomes. They do not express NCAM or CAD,
and they do not contain CK18 filaments [71, 74],
Type 4 CLENDOs are predominantly round cells with no intracellular
vacuoles [70]. They have short filipodia radiating around the cell margins.
Similar to type 3 cells, type 4 cells express factor Vlll-related antigen and ACE
throughout the cytoplasm, acLDL uptake is abundant in lysosomes, they do not
express NCAM or CAD, and they are CK18 negative [71, 74],
Expression of the intermediate filament CK18 may be one of the more
important distinctions among the unique classifications of endothelial cell types.
The cytokeratin 18 positive (CK18+) phenotype is rare within CLENDOs of the
bovine CL [70, 76, 77]. Morphologically and functionally, CK18+ CLENDOs are
different from the more abundant cytokeratin 18 negative (CK18-) cells, but
appear morphologically similar to CK18+ endothelial cells of the bovine aorta
[76]. Factor VIII expression is 5-fold lower in CK18+ CLENDOs than CK18-
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CLENDOs, and acLDL uptake is 10-fold lower. Functionally, CK18+ and CK18CLENDOs differ in cytokine production in response to TN F stimulation. TN Finduced granulocyte-macrophage colony-stimulating factor (G M -C SF) is
expressed only by CK18- CLENDOs, and TNF-induced ‘regulated on activation,
normal T cell expressed and secreted’ (RANTES) mRNA levels are 200 times
higher in CK18- CLENDOs than CK18+ CLENDOs [75], Conversely, CK18+
CLENDOs express mRNA for prostaglandin E 2 (PG E2) and PGF2a receptors,
while CK18- CLENDOs do not [78].
From the aspects of angiogenesis and angioregression, expression of
angiopoeitins (Ang 1 and Ang 2) among the different CLENDO types is
interesting. Both CK18+ and CK18- CLENDOs do not contain Ang 1 mRNA, and
only CK18- contain Ang 2 mRNA [79], Ang 1 and Ang 2 mRNA are present in
the developing and functional CL [26]. Wulff et al. (2000) localized Ang 1
expression in steroidogenic and endothelial cells throughout the human CL [80],
but its localization within the bovine CL has not been reported. Although its
source is unknown, Ang 1 stimulates sprouting and maturation of blood vessels
in vitro, while Ang 2 is a competitive inhibitor, binding to the same tyrosine kinase
with immunoglobulin and epidermal growth factor homology domains (Tie-2
receptor), but not activating the intracellular signals of angiogenesis. Also, levels
of Ang 2 are elevated during luteal regression, suggesting that Ang 2 has a role
in angioregression [26, 63].
The endothelium is a major target for cytokines in most tissues.
Endothelial cells serve as part of the barrier or ‘gatekeeper’ between the blood
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stream and the tissues, determining the traffic and action of cells and molecules
within the body [81]. As previously mentioned, there are large numbers of
endothelial cells in the CL and thus endothelial-immune cell interactions are
reasoned to be important in luteal function. Treatment of CLENDOs with the
cytokine IFNG alters their morphology, which might lead to important functional
alterations. For instance, type 1-4 cells become flattened and enlarged upon
IFNG treatment [63]. Type 3 cells form large, lipid-filled vacuoles, possibly
indicating the onset of senescence [73]. IFNG also elevates CAD levels in type 1
cells, and disturbs actin structure and reduces fibronectin content in type 1, 3,
and 4 cells [72]. As a result, IFNG could lead to an anti-proliferative effect, which
is observed in type 1-4 CLENDOs [73]. Also, stimulation of CLENDOs with TNF,
IFNG, or TN F + IFNG results in increased secretion of CCL2, suggesting a role
for immune-mediated mechanisms in luteal function [48]. Similarly, placement of
CLENDOs in co-culture with activated immune cells also results in increased
CCL2 secretion [82].
In summary, the four types of CLENDOs within the bovine CL are
morphologically and physiologically unique, but contribute to the formation,
function, and regression of the microvasculature. Important distinctions based
upon CK18 expression, PGF2a receptor presence, and response to cytokines
reveal that further study is required to determine the physiologic significance of
these cell types during different phases of CL function, both during the estrous
cycle and pregnancy.
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Interferon Gamma
Interferons were first characterized in 1957 by Isaacs and Lindenmann as
substances that interfere with viral replication [83]. Their antiviral capabilities led
to their discovery, but it is now known that interferons are one of the main
classes of cytokines naturally produced in the body with far-reaching implications
beyond the fight against disease. Specifically, interferons influence the overall
function of the immune system and therefore the body as a whole.
There are two major groups of interferons, type I and type II, which are
classified primarily by structural homology and receptor binding specificity. Type
I interferons are separated into two main types, IFNa and IFNp [84], but also
include IFN5, IFNe, IFN k , IFN x, and IFNco [85]. IFNa is a family of related
proteins primarily produced by leukocytes, and IFNp is a single protein produced
mainly by fibroblasts. The type I interferons are widely expressed and largely
induced in response to viral infections [84, 86]. In contrast, IFNy (IFNG ) is the
only type II interferon. It is called an interferon solely on the merits of its antiviral
effects, but it is a completely different molecule from the other interferons both in
structure and action [87].
IFNG was originally referred to as ‘immune interferon’ or ‘immune-induced
interferon’ because it is produced by lymphocytes following antigenic stimulation;
whereas ‘classical interferons’ are molecules produced by leukocytes or non
lymphoid cells [88, 89], As the old nomenclature describes, IFNG is primarily
activated by immune and inflammatory stimulation. It was thought to be
produced solely by T lymphocytes through MHC class I and II antigenic
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stimulation and by natural killer cells through TNF and macrophage cofactor
stimulation. Recently however, professional antigen presenting cells such as
monocytes/macrophages have also been identified as sources of IFNG [90, 91].
IFNG elicits major effects on cells of the immune system including
regulating MHC class I and II expression on mononuclear phagocytes,
endothelial cells, and epithelial cells. IFNG also activates and regulates the
differentiation and function of monocytes/macrophages (hence IFNG once being
known as ‘macrophage-activating factor’ [92]), and regulates B cell functions
such as immunoglobulin production and isotype/class switching [84, 90, 91].
IFNG has a major role in inflammatory response, most notably through its
synergistic action with TNF. The synergistic actions of IFNG /TNF will be
discussed in detail later, but briefly, IFNG increases the expression of TNF
receptors on the surface of cells [93, 94], and enhances TNF production by
macrophages in an endotoxin (lipopolysaccharide)-induced inflammatory
response [90],
The wide variety of IFNG actions is perhaps due to the relatively
ubiquitous expression of IFNG receptor throughout the body [90, 95]. The IFNG
receptor (IFNG R) is a transmembrane, multi-chain structure composed of two
ligand binding units, IFNGR1, and two signal transduction units, IFNGR2 [84, 91]
(Fig. 1). The extracellular domain of the receptor is the ligand binding site, while
the intracellular domain functions in signal transduction. IFNGR1 is constitutively
expressed and plays the critical role in receptor-binding recognition. In contrast,
IFNGR2 has the major role of signal transduction and is the limiting factor in
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IFNG action. It is also constitutively expressed, but at low levels and under tight
regulation [84]. Upon dimerization of the IFNG ligand subunits [96], subsequent
binding to IFNGR1 occurs, resulting in IFNGR1 and IFNGR2 association [84].
The IFNG receptor alone is incapable of inducing an intracellular signal.
Therefore, it associates with Janus tyrosine kinases (enzymes named for the
Roman God Janus who had two faces). The Janus kinases (Jaks) have two
faces/sites, one a binding site to associate with the IFNG receptor and the other
a catalytic site with tyrosine kinase phosphorylation capabilities [97, 98]. In
particular, IFNGR1 associates with Jak1 and IFNGR2 with Jak2 [84] (Fig. 1).
These Jaks, in turn, interact with signal transducers and activators of
transcription (Stat) signaling cascades.
Figure 1. IFNG signaling pathway.
IFNGR1
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IFNGR2
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When the IFNGR1 and IFNGR2 subunits interact, Jak1 and Jak2 are
activated by Jak2 autophosphorylation and subsequent transphosphorylation of
Jak1 [91] (Fig. 1). The activation of Jak1 attracts a particular Stat, S ta tl, from
the cytoplasm to associate with the receptor complex [99] (Fig. 1). Upon
association, Statl is phosphorylated and homodimerizes [100] to become
gamma interferon activated factor (GAF) [101] and translocates to the nucleus
(Fig. 1). In the nucleus, GAF targets gamma interferon activated site (GAS)
elements on DNA to initiate or suppress transcription of IFNG-regulated genes
(Fig. 1), such as the transcription factor interferon regulator factor 1 (IRF-1) [85].
IRF-1 is a member of an ever growing family of transcription factors known
as interferon regulatory factors (IRFs). It was first characterized as a regulator of
virus-inducible enhancer-like elements of the human IFNp gene [102]. IRF-1 is
expressed at low levels in unstimulated cells but is greatly induced upon
stimulation with cytokines, such as IFNG and TN F [103]. IRF-1 activation is
important in the development of T lymphocyte subsets (C D4+ and C D8+) [104]
and is capable of inducing typical IFNG functions, such as increasing MHC
expression [103].
The most crucial action of IRF-1 is its ability to activate transcription and
interact with transcription factors, such as nuclear factor kappa B (NF- k B). IRF-1
as a transcription factor controls the expression of many different target genes,
including cyclooxygenase 2 [105], an enzyme responsible for prostaglandin
production in inflammation, and caspases 1 and 7, which regulate apoptosis [96].
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The role of IRF-1 in apoptosis can be either pro- or anti-apoptotic. IRF-1
activation alone does not lead to cell death unless accompanied by the actions of
certain cytokines (fibroblast-associated (Fas) ligand and TN F + IFNG) or as
result of a pathologic condition [103]. The pro-apoptotic actions of IR F-1,
particularly induced by treatment of cells with TN F + IFNG, are of interest in the
present study. Furthermore, IFNG-activated IRF-1 inhibits TNF-induced NF- k B
activation, which is a protective, anti-apoptotic pathway [106]. Conversely, IRF-1
is thought to contribute to cell survival in certain physiologic situations [103].
In the bovine CL, IFNG mRNA is detectable at all stages of the estrous
cycle [46], Penny and co-workers (1999) reported the presence of IFNG mRNA
around the time of luteal regression, which coincided with an infiltration of T
lymphocytes, the primary source of IFNG [36]. In addition, IFNG mRNA declines
during late diestrus (day 18) and at 1h post PGF2a-induced luteal regression [46].
Currently, there are no protein or absolute quantitative mRNA data regarding
IFNG expression in the bovine CL.
Despite the relative lack of information available about IFNG expression,
there are several postulated roles of IFNG in the bovine ovary. IFNG enhances
Fas ligand (FasL)-induced killing of granulosa, theca [107], and luteal cells [108].
IFNG augments the expression of MHC class II molecules on bovine
steroidogenic luteal cells [109] and microvascular endothelial cells of the CL
(type 2 in particular) [110]. Along with promoting immune response mechanisms,
IFNG enhances the production of PGF2a by bovine luteal cells and inhibits LHstimulated progesterone production [111].
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IFNG signaling in bovine luteal cells is transduced by the Jak-Stat
pathway, but does not alter NF- k B expression. S ta tl, but not k B a , protein levels
are significantly increased following IFNG treatment, indicating signaling through
the Jak-Stat, but not NF- k B pathway. Also, IFNG influences the transcription and
translation of IRF-1 [112].

Tumor Necrosis Factor Alpha
TN F was first described as an endotoxin-induced factor produced by
macrophages [113] that causes necrosis of tumors [114]. For several years, the
focus of TNF research centered on cancer biology [115], Since the time of its
characterization however, TN F is now known to regulate immune responses
(inflammatory and apoptotic pathways), cellular proliferation and differentiation,
tumorigenesis, and viral replication [116,117]. Additionally, as TN F has a major
role in regulating immune cell activity, it is also involved in pathological
conditions, including autoimmune disorders, such as rheumatoid arthritis, irritable
bowel syndrome [118], and psoriasis [119].
TN F is a cytokine produced primarily by macrophages, but also by B and
T lymphocytes, mast cells, fibroblasts, endothelial cells, and neuronal tissue. It is
a 26-kDa transmembrane protein cleaved by the metalloprotease TNF-alphaconverting enzyme (TACE) to a 17-kDa soluble form. TNF is arranged in stable
homotrimers and is active in membrane-bound or soluble forms [117, 120].
TNF exerts its biological functions via the TNF receptor superfamily,
particularly TNF-receptor 1 (TN F-R 1) and TNF-receptor 2 (TNF-R2). Membrane-
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bound TNF readily activates both receptors, while soluble TN F predominantly
signals through TN F -R 1. TNF-R1 is constitutively expressed in most tissues,
while TN F-R 2 is highly regulated and restricted to cells of the immune system.
Both receptors contain a pre-ligand-binding assembly domain (PLAD) that results
in receptor trimerization upon activation by TNF [120],
The intracellular domains of the TN F receptors are different and of
functional importance. TNF-R1 contains a protein-protein interaction domain
referred to as a death domain (DD) that is crucial to the death-inducing activity of
the receptor [120]. Upon binding of TNF, an inhibitory protein called the silencer
of death domain (SO D D ) is released [117] (Fig. 2). The DD can then recruit
other proteins containing DD, such as TN F receptor-associated death domain
(TRADD). TRADD in turn attracts Fas-associated death domain (FADD), which
initiates signaling events through caspase activation that lead to apoptosis [121]
(Fig. 2).
TRADD also attracts TNF-R-associated factor 2 (TRAF2), which can lead
to anti-apoptotic pathways. TRAF2 binding to TRADD results in the production of
the anti-apoptotic protein cellular inhibitor of apoptosis protein-1 (clAP-1) (Fig. 2).
Also, TRAF2 attracts NF-icB-inducing kinase (NIK) and receptor interacting
protein (RIP), which separately attract inhibitor of k B kinase (IKK), activating NFkB

(Fig. 2). Unlike TN F-R 1, TN F-R 2 does not signal through a DD. Instead, it

directly recruits TRAF2, and signals through the NF- k B pathway, or induces the
expression of membrane-bound TN F which subsequently activates TNF-R1 [117,

121].
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Figure 2. TN F signaling pathway.
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As mentioned, a commonality between TNF-R1 and TN F-R 2 is their ability
to induce NF-k B activation [122]. NF- k B is a transcription factor located in the
cytoplasm associated with an inhibitor complex, inhibitor k B (Ik B), in an
unactivated state. Upon activation of IKK, Ik B is phosphorylated and
relinquishes NF- k B, which then translocates to the nucleus and induces gene
expression (Fig. 2). NF- k B activation increases expression of inflammatory
proteins [123], and interestingly, anti-apoptotic molecules such as clAP-1 [121],
cellular FLICE-like inhibitory protein (cFLIP), and B-cell leukemia/lymphoma 2
(Bcl-2) [124] (Fig. 2). The latter products of NF- k B activation lead to an
interesting paradigm of TNF receptor signaling, particularly TN F -R 1. Ligand
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binding can lead to both pro-apoptotic and anti-apoptotic pathways via activation
of DD-associated proteins. Also, the absence or inhibition of NF- k B activity
results in increased cellular susceptibility to TNF-induced apoptosis, whereas
activation of NF- k B protects against it [121]. These pro- and anti-apoptotic
actions of TN F are of particular interest in the current study.
In the CL, the presence and localization of TNF and its receptors have
been extensively studied in numerous species. In the rabbit, lipopolysaccharideinduced TN F production in the regressing CL is elevated, but also present in the
early CL (day 5) [125]. There are large numbers of macrophages in the
regressing CL of the rabbit, suggesting that macrophages are the source of TNF.
But TNF secretion by the early CL and the scarcity of macrophages indicate that
other cell types within the rabbit CL produce TN F [125]. Recent studies
describing TN F secretion in the porcine CL have further added to the confusion
of the cellular sources of TN F within the CL.
TN F protein is present in the porcine CL during the estrous cycle and
pregnancy with no difference between the two physiologic states [126].
According to Hehnke-Vagnoni and co-workers (1995) [126], TN F is localized to
the endothelial cells of functional CL, while macrophages are rarely seen and not
associated with TN F staining. No TN F was detected in CL undergoing functional
luteal regression [126]. In contrast, Zhao and co-workers (1998) [127] report that
macrophages are the major source of TN F in the porcine CL. TN F is co
localized to cells that also stain positively as macrophages, whereas endothelial
cells consistently lacked TN F staining. A bioassay of the individual cell
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populations incubated with lipopolysaccharide similarly revealed macrophages as
the major source of TNF secretion in the porcine CL [127]. In the pig, TNF
receptors are present and functional within the CL throughout the estrous cycle
and early pregnancy. Receptor concentration increases in the late luteal stage of
the estrous cycle (day 15) compared to the CL of pregnancy on the same day,
suggesting a role for TNF in luteal regression [128]. TNF also induces apoptosis
of porcine luteal cells [129], TN F receptors are localized to small luteal cells
(small steroidogenic and endothelial cells) of porcine CL [130], implying a
possible autocrine action of TN F on endothelial cells of the CL.
In the bovine CL, TN F protein increases around luteal regression, days
13-18 of the bovine estrous cycle, but there is no difference in TN F mRNA
expression throughout the estrous cycle [131]. Intraluteal TNF concentration
increases after progesterone begins to decline, but there is no increase in
systemic concentrations of TN F [132], TNF-R1 mRNA levels are greatest in the
early luteal phase (days 3-7) [131]. In CLENDOs, TNF receptor protein
expression is seen in type 3 CK18- CLENDOs of the estrous cycle having two
binding affinities (low and high) for TNF. TNF-R1 mRNA is expressed by the
CLENDOs, but the levels are less than the CL as a whole [133],
In the bovine CL of pregnancy, TN F mRNA is present in equal amounts
throughout gestation, but TN F receptor protein expression is higher during the
early and late stages of pregnancy as compared to the middle of pregnancy
[134].
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TN F has a variety of effects on the CL. In vitro, TNF alone and in
combination with IFNG increases PGF2a synthesis by bovine luteal cells [135].
TNF does not affect basal progesterone production but does suppress LHstimulated progesterone production. In vivo, low concentrations of TN F promote
luteal regression and shorten the estrous cycle, whereas high concentrations
activate CL function and prolong the estrous cycle in cattle [136]. A low dose of
TNF (1 pg) stimulates PGF2a production but does not affect progesterone
production. Conversely, a high dose of TNF (10 pg) stimulates progesterone and
the luteotrophic PGE2 [136]. These divergent effects of TNF highlight its
potential role in regression of the CL, suggesting different concentrations could
stimulate either pro- or anti-apoptotic pathways.
TNF promotes cell proliferation in rat ovarian theca-interstitial cells [137],
yet induces apoptotic cell death in bovine CLENDOs [138, 139], TNF-R1 mRNA
expression is higher in endothelial cells of the CL than steroidogenic cells, and
TNF induces time- and dose-dependent death in endothelial cells [138]. It is
hypothesized that progesterone within the CL regulates cell survival in relation to
TNF-induced death. Physiologic levels of progesterone prevent TNF-induced
death of CLENDOs [138], and steroidogenic cells, which produce progesterone,
are consistently protected against TNF-induced death [138]. Other luteolytic
actions of TN F include increasing endometrial production of PGF2a [140],
enhancing MHC class I expression on bovine luteal cells [135], and inhibiting
luteotrophic estradiol production in the porcine CL [141].
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With regard to the CL of pregnancy, TNF plays similar roles in its
regression as mentioned for the CL of the estrous cycle, but TNF also potentially
contributes to the maintenance of the CL of pregnancy. In vitro, TN F stimulates
PGE 2 and PGF 2 « production, which increase progesterone output by luteal cells.
The output of PGE2 and PGF2a by the CL at day 200 of gestation is greater than
at day 14 of the estrous cycle, and progesterone production from day 200 is
increased by PGE2 but not LH. Also, there are higher numbers of PGE2
receptors in pregnant versus nonpregnant ewes [142], and large luteal cells are
known to produce progesterone in response to PGE2 [143]. Therefore, TNF
stimulates the production of PGE2 and PGF2a by the CL of pregnancy, and
indirectly increases its progesterone production [144].

Synergy of Tumor Necrosis Factor Alpha and Interferon Gamma
TNF and IFNG are two cytokines that influence the actions of each other.
The synergistic action of TNF and IFNG was first documented as a cytotoxic
effect in which the two cytokines in combination were more potent than either
cytokine alone [145]. This synergy of TN F and IFNG to induce cell death has
been documented for rat hepatocytes [146], mouse luteal cells [147], and bovine
luteal cells [135, 148]. Originally, the synergistic action of TN F and IFNG was
attributed to the regulation of TN F receptors by IFNG. That is, IFNG induces the
synthesis of TN F receptors, resulting in an upregulation of both types of TNF
receptors (TNF-R1 and TN F-R 2) on cells [94]. The enhancement of TNF
receptors, and thus TNF binding, was thought to be the mechanism for the
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cytotoxic effect [93, 149, 150]. However, others contend that IFNa and IFNp do
not have a significant effect on TN F receptors, but nonetheless enhance the
cytotoxic activity of TNF [151]. Alternatively, intracellular signaling might account
for the synergistic action of TN F and IFNG.
Intracellular signaling has a prominent role in regulating the effects of
cytokines. S tatl activation by IFNG and NF- k B activation by TN F are necessary
for the induction of genes potentially important for mediating their cooperative
activities, such as IRF-1. TNF and IFNG independently and synergistically
promote the expression of IRF-1 [152]. IRF-1 inhibits NF-KB-mediated activation
of cell survival signals through modulation of NF- k B transcriptional activity [106].
Therefore, IRF-1 induction by TNF and IFNG alone or synergistically might
prevent activation of the anti-apoptotic NF- k B pathway, leading to cell
death/apoptosis (Fig. 3).
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Figure 3. Synergistic death effect of TN F and IFNG.
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Other mechanisms by which TN F and IFNG promote death and
destruction of tissues include augmenting Fas-mediated apoptosis and
enhancing elements of an immune response. In the ovary, TN F and IFNG
potentiate Fas-mediated apoptosis of granulosa and luteal cells [108, 153, 154],
increase MHC class I [155] and intercellular adhesion molecule I (ICAM-1)
expression [156], and enhance the secretion of CCL2 [48, 8 2 ,1 5 7].

Lectins
Lectins are a class of non-immunologic proteins and glycoproteins that
bind specifically to carbohydrates. They were originally referred to as
hemagglutinins or phytoagglutinins because they originate from plant extracts
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and have the ability to agglutinate erythrocytes [158]. Interestingly, ricin, the
deadly toxin occasionally used by extremist groups in terrorist plots, was the first
isolate from a plant, the castor bean (Ricinus communis), to show properties of
hemagglutination. ‘Lectin’ comes from the Latin term legere, meaning to pick out
or choose. The name lectin was chosen due to the blood-type specific
hemagglutination exhibited by some of the extracts from plants [159]. For
example, the extract from Griffonia simplicifolia (also known as Bandeiraea
simplicifolia) has almost exclusive specificity for blood type B [160]. The name
lectin now encompasses any non-immune origin, sugar-specific agglutinin,
regardless of source (plant, animal, microbial) and blood type specificity [158].
Lectins from sources other than plants, such as animals, viruses, bacteria,
protozoa, etc., are rarely used in the more common applications of lectins [161],
which include precipitating carbohydrate-containing macromolecules, and
agglutinating plant and animal cells along with bacteria and yeast [162],
Because lectins bind carbohydrate moieties on cell surfaces, they can be
inhibited by sugars for which they are specific. For example, concanavalin A
binds to D-mannose/D-glucose [163, 164]. Placing D-glucose in solution with
concanavalin A inhibits binding of concanavalin A to cell surfaces.
Concanavalin A (ConA), isolated from the jack bean (Canavalia
ensiformis) [165], is the most extensively studied lectin [163]. It serves as a
structural probe for carbohydrates in solution and on cell surfaces. It is also a
lymphocyte mitogen, anticancer agent, reagent for differentiating normal from
malignant cells, and model for antibody-antigen reactions [158, 164], ConA is an
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exclusively protein lectin. It is one of the few lectins not covalently bound to a
carbohydrate (glycoprotein), making it similar to wheat germ agglutinin (WGA),
another protein lectin [164].
Bandeiraea simplicifolia I (BS-I), also known as Griffonia simplicifolia I,
isolated from Bandeiraea simplicifolia seeds, is a type B blood specific
hemagglutinin [166]. Bandeiraea simplicifolia seeds yield two lectins with
different sugar-binding specificity, BS-I binds D-galactose, while BS-I I binds 2acetamido-2-deoxy-D-galactose. Unlike ConA, BS-I is a glycoprotein, binding
specifically to a-D-galactose [164].
Lectins are classically used for cell agglutination purposes. They primarily
interact with carbohydrate moieties on the cell surface in the form of glyco
proteins and glycolipids. However, lectins can also interact with glycoproteins
and glycolipids within organelles such as chloroplasts and mitochondria, if the
cell has been permeabilized. Additionally, lectins have been used as membrane
structural probes, determining the localization and function of carbohydrates on
the plasma membrane or intracellular membranes [163]. Of relevance to the
present study is their ability to be labeled, with either radioisotopes or
fluorophores, to quantitatively assess lectin binding sites on cells. Also of
significance to the present study is the use of lectins coupled to certain media,
such as magnetic beads, to purify specific cell populations.
In reproductive physiology, lectins are used to purify mixed cell
populations. In particular, the lectin BS-I has been used to isolate CLENDOs
from a mixed population of cells from the bovine CL containing small and large
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steroidogenic cells, fibroblasts, pericytes, immune cells, and endothelial cells [62,
167-171], CLENDOs bind the lectins BS-I and ConA, among others. BS-I is a
constitutive endothelial cell marker throughout the developmental stages of the
CL, while ConA exhibits a broad binding expression pattern throughout the ovary
[20], But other authors have indicated that BS-I binding differs between
CLENDO phenotypes and CLENDOs of the estrous cycle versus CLENDOs of
pregnancy [172], These conflicting data indicate further study of lectin
expression in CLENDOs is required.
Also of interest to the present study is lectin expression with regard to
angiogenesis. Particularly, endothelial phenotype, with respect to lectin
expression, is thought to change in migrating versus contact-inhibited cultures of
bovine aortic endothelial cells [173]. As the CL is a tissue that undergoes
angiogenesis, maintenance of the vasculature, and angioregression, changing
lectin expression throughout the course of the estrous cycle and pregnancy could
be of significance to the overall processes of luteal formation, function, and
regression.

Objectives and Hypotheses
To our knowledge, there are few studies that directly compare CL of the
estrous cycle versus pregnancy, and even fewer that assess the luteal
vasculature. Therefore, the current study set out to compare structural and
functional attributes of CLENDOs of the estrous cycle with those of pregnancy to
determine if reproductive status contributes to the diversity of microvascular
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endothelial cells. The parameters assessed were lectin binding, Ik B cx
degradation, IRF-1 expression, TN F and CCL2 production and secretion, and
apoptosis. The current hypotheses are as follows: 1) There is no difference in
lectin expression between CLENDOs of the estrous cycle and pregnancy. 2)
There is no difference in TNF-induced k B a degradation between CLENDOs of
the estrous cycle and pregnancy. 3) There is no difference in TN F- and IFNGinduced IRF-1 expression between CLENDOs of the estrous cycle and
pregnancy. 4) CLENDOs are a source of TNF. 5) There is no difference in
IFNG-induced TN F secretion between CLENDOs of estrous cycle and
pregnancy. 6) There is no difference in cytokine-induced production of CCL2
between CLENDOs of the estrous cycle and pregnancy. 7) TN F and TNF +
IFNG are cytotoxic to CLENDOs of the estrous cycle and pregnancy, while IFNG
alone is not.
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CHAPTER II

MICROVASCULAR ENDOTHELIAL CELLS OF THE BOVINE CORPUS
LUTEUM: A COMPARATIVE STUDY OF THE ESTROUS CYCLE AND
PREGNANCY

Introduction
The corpus luteum (CL) is a temporary endocrine gland that forms within
the ovary following ovulation and contributes to estrous/menstrual cycle regularity
and the establishment and maintenance of early pregnancy [14]. Aside from its
transient nature, an intriguing aspect of the CL is its adaptable lifespan. In
domestic livestock, the CL remains functional for as few as 15-18 days to as
many as 200-300 days depending upon species and reproductive status of the
animal [174]. In the bovine for instance, the CL develops, functions, and begins
to regress within 17-18 days of the estrous cycle, or it can have a functional
lifespan of more than 200 days during pregnancy [64]. Similarly, the functional
lifespan of ovine CL varies from 15-16 days during the estrous cycle to
approximately 50 days during pregnancy [175]. In fact, in most placental
mammals the continuation of luteal function extends well beyond the
estrous/menstrual period and is required for the establishment and maintenance
of pregnancy for a significant portion of the first trimester [14], Thus, plasticity of
the CL would appear to be critical to its function: alterations in cellular
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composition and hormonal responsiveness permit adaptations to reproductive
status (i.e., estrous cycle -> pregnancy).
Historically, relatively few studies have directly assessed attributes of the
CL of the estrous cycle versus the CL of pregnancy. Those that have compared
the two physiologic states have primarily focused on the composition and
physiology of the steroidogenic cell populations. For example, in the ovine,
corpora lutea of the estrous cycle and of pregnancy are of similar size, weight,
and cellular composition [65, 175,176], Steroidogenic cells in both types of
corpora lutea comprise about 60% of the tissue [65], and have comparable
volume density, cytoplasmic to nuclear ratio, cell number/mm3, and cell volume
[175]. Yet the “small” steroidogenic cells of corpora lutea of pregnant ewes are
larger, and both the “small” and “large” cells are less responsive to luteinizing
hormone (LH) stimulation than the comparable steroidogenic cells of corpora
lutea from nonpregnant ewes [176]. A similar distinction in LH response is also
observed in steroidogenic cell populations of bovine corpora lutea [177].
Progesterone concentration in corpora lutea of pregnant ewes is greater than in
corpora lutea of non-pregnant ewes, even though no differences exist in luteal
weight or circulating concentrations of progesterone [176]. In the bovine,
however, higher progesterone concentrations exist in the milk of pregnant versus
nonpregnant cows [178],
From the standpoint of luteal regression, a few studies have compared
key components of the process in corpora lutea under different physiological
states (nonpregnant vs. pregnant), such as prostaglandin receptor expression
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and immune function. W iepz and colleagues (1992) indicate that while ovine
corpora lutea possess 7-10-fold more receptors for prostaglandin F2a (P G F2a)
than prostaglandin E2 (PG E2), regardless of reproductive status, there are
generally more of both types of receptors in corpora lutea of pregnant than
nonpregnant ewes [142]. PGF2ct is a known luteolytic agent [34], while PGE2 is
luteotrophic [136], delays luteal regression, and suppresses PGF2a actions [14].
Therefore, it appears that continuation of the CL into pregnancy in the ewe is not
due to downregulation of prostaglandin receptors, thereby rendering the CL
unresponsive to the luteolytic PGF2h. Instead, other mechanisms must contribute
to luteal regression and be suppressed or inactive for the CL to maintain its
structure and function throughout pregnancy. One such possibility is the role of
the immune system in luteal regression. In the ovine, bovine, and equine,
expression of major histocompatibility (M HC) class II molecules is diminished in
corpora lutea of pregnant animals compared to cyclic animals [38, 44, 45], This
suggests that mechanisms of immune suppression exist within the CL of
pregnancy to sustain its function. Consistent with these observations, luteal
regression at the end of pregnancy in the ovine is reported to be similar to that of
the estrous cycle (e.g., characterized by endothelial cell loss and immune cell
infiltration [175]), but occurs over an extended period of time (i.e., several weeks
[179]) in the postpartum ewe [65].
The aforementioned studies focus almost exclusively on the steroidogenic
cell population of the CL, but the CL is comprised not only of “small” and “large”
steroidogenic cells, but also endothelial cells, fibroblasts, and immune cells [17].
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Endothelial cells make up about 50% of the midcycle CL [17] and are vital in the
formation, function, and regression of the tissue. Angiogenesis is essential to the
development of the gland, as an inadequate vasculature is associated with
reduced luteal function [23], Stability of the vasculature is paramount to the
endocrine function of the gland, importing nutrients, substrates, and hormones,
and conveying progesterone to its target tissues [18]. Endothelial cells of the CL
are among the first cells to undergo apoptosis during luteal regression, thereby
eliminating the blood supply to the tissue and dictating its fate [31]. Since
endothelial cells are the first cell type to be eliminated during regression of the
CL, their maintenance in the CL of pregnancy would lead one to believe that
microvascular endothelial cells of the CL (CLENDOs) of the estrous cycle and of
pregnancy differ. Potential physical and functional differences in CLENDOs
could help explain how the CL of the estrous cycle has a defined lifespan of 1718 days, whereas the CL of pregnancy is maintained for as many as 200 days.
To our knowledge, there is currently only one study in which bovine
CLENDOs of the estrous cycle and pregnancy have been directly compared.
Plendl et al. (1996) reported different expression of surface carbohydrates
(lectins) based on reproductive status and cellular morphology in bovine
CLENDOs [172]. Specifically, CLENDOs of pregnancy of the cobblestone
phenotype (versus arcuate) have significant binding capacity for the lectins
Bandeiraea simplicifolia I (BS-I), wheat germ agglutinin (WGA), and concanavalin
A (ConA) compared to the estrous cycle [172]. Also, spontaneous angiogenic
activities, such as cellular migration in band-like structures and formation of ring
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like-structures in vitro, are observed exclusively in CLENDOs of pregnancy [172].
These results indicate that cellular recognition markers, such as lectins, differ
between CLENDOs of pregnancy and the estrous cycle. Physical differences
such as these infer different functions of these cells within the microvasculature,
particularly with regard to angiogenic capabilities.
Considering the relatively few studies which have directly compared CL of
the estrous cycle versus pregnancy, and even fewer studies assessing the
diversity of the luteal vasculature, the current study determined if reproductive
status contributes to the diversity of luteal microvascular endothelial cells. Lectin
binding was compared between CLENDOs of the estrous cycle and pregnancy
as a basis of physical/morphological attributes. Responsiveness to the cytokines
tumor necrosis factor alpha (TNF) and interferon gamma (IFNG ) were assessed
as functional attributes to determine if immune mechanisms are similar between
CLENDOs of the estrous cycle and pregnancy. Specifically, intracellular
signaling, cytokine production, and cell death were evaluated.

Materials & Methods
Reagents
Plastic culture vessels were purchased from Corning, Inc. (Corning, NY) and
Becton-Dickinson (Franklin Lakes, NJ). NUNC-lmmuno MaxiSorp 96-well ELISA
plates were purchased from Nalge Nunc (Rochester, NY). Microvascular
endothelial cell medium (EG M -2M V) was obtained from Cambrex Bioscience
(Walkersville, MD). Minimum Essential Medium Eagle (MEM), Hanks’ Balanced
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Salts (HBSS), fetal bovine serum (FBS), 0.25% trypsin/0.2% EDTA, FITC-labeled
BS-I and ConA, a-D-galactose, a-D-glucose, monoclonal anti-p-actin, and
protease and phosphatase I & II inhibitor cocktails were purchased from Sigma
(St. Louis, MO). Gentamicin was obtained from Invitrogen (Carlsbad, CA). HRPlinked anti-rabbit IgG was purchased from Cell Signaling Technology (Danvers,
MA). Interferon regulatory factor 1 (IR F-1) and inhibitor kappa B alpha (k B a )
antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Enhanced chemiluminescence reagent kit (ECL) was from Amersham
Biosciences (Piscataway, NJ). Recombinant murine TN F was purchased from
United States Biological (Swampscott, MA). Recombinant bovine IFNG and
bovine TN F screening sets were purchased from Pierce Biotechnology
(Rockford, IL). Human monocyte chemoattractant protein 1 (CCL2) DuoSet
ELISA Development System was from R&D Systems (Minneapolis, MN). APOBrdU Assay was purchased from Phoenix Flow Systems Inc. (San Diego, CA).
Etanercept was a gift from Dr. Bo R. Rueda. All remaining reagents and
materials were purchased from Sigma, V W R International, Inc. (West Chester,
PA), or Fisher Scientific (Pittsburg, PA).

Cell Culture
Aliquots of purified CLENDOs of midcycle (day 12) and early pregnancy (day 60),
isolated as previously described [48], were used in all experiments. The cells
were cultured in EGM -2 MV with 3% FBS, growth factors [recombinant long R
insulin-like growth factor-1, recombinant human fibroblast growth factor-B,
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recombinant human vascular endothelial growth factor, recombinant human
epidermal growth factor, hydrocortisone, ascorbic acid, *Note: exact
concentrations of growth factors are proprietary information*, antibiotic (30 pg/ml
gentamicin sulfate), and antifungal (15 ng/ml amphotericin-B)] in a 37°C
humidified incubator of 95% air and 5% C 0 2. Bovine pulmonary arterial
endothelial cells (BPAECs) were cultured in MEM with 10% FBS and 20 pg/ml
gentamicin in a 37°C humidified incubator of 95% air and 5% C 0 2.

Lectin Binding Experiments
CLENDOs of midcycle (passage 5) and early pregnancy (passage 5) were
seeded at a density of 30,000 cells/ml in T25 flasks. At confluence, cells were
removed from each flask by enzymatic treatment using HBSS modified with 2
mM EDTA and 0.25% trypsin with 0.2% EDTA. The cell suspensions were spun
at 200 x g for 10 min by centrifugation, counted using trypan blue dye exclusion,
and concentrated at 400,000 cells/ml. One ml of the cell suspension was placed
into five 12 x 75 mm polystyrene round bottom test tubes and centrifuged at 250
x g for 10 min. Cell pellets were resuspended and incubated with 100 pi PBS
(control) or FITC-labeled BS-I or ConA at a concentration of 2.5 pg/ml for 1 h at
4°C. Additional controls included samples containing the competing sugar to BSI and ConA (200 mM a-D-galactose and a-D-glucose, respectively) [172]. After
the 1 h incubation, cells were rinsed with HBSS modified with 2 mM EDTA and
centrifuged for 10 min at 250 x g. Cell pellets were then fixed by resuspension in
375 pi PBS and 125 pi 4% paraformaldehyde (1% final concentration). The fixed
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cells were placed on 12 x 75 mm cell strainer (35 pm) capped polystyrene round
bottom test tubes and centrifuged for 5 min at 200 x g in preparation for flow
cytometric analysis. The cells were analyzed using a four-color, dual-laser
FACSCalibur machine (BD Biosciences, Palo Alto, CA) and data were collected
using Cellquest (BD Biosciences, Palo Alto, CA). Mean fluorescence lectin
binding was calculated using WinMDI software (Joseph Trotter, Scripps
Research Institute). BPAECs (200,000 cells/ml) were used as a positive control
for comparative purposes [180,181],

Cytokine-stimulated Intracellular Signaling Experiments
TNF-induced Degradation o f IfcBa
CLENDOs of midcycle (passage 6) and early pregnancy (passage 6) were
seeded at a density of 30,000 cells/ml and cultured in 6-well plates to confluence
(1-2 weeks). Prior to cytokine treatment, cells were equilibrated in pre-warmed,
gassed, basal medium (EBM -2) for 2 h. CLENDO cultures were exposed in
duplicate to vehicle (control) or TN F (50 ng/ml) for 15 min. After cytokine
treatment, the cells were placed on wet ice to terminate the experiment. The
conditioned medium was removed and the cells rinsed with cold PBS and then
lysed using a lysis buffer (20 mM Tris HCI pH 7 .4 ,1 5 0 mM NaCI, 1 mM EDTA, 1
mM EGTA, 1% Triton X-100) containing protease and phosphatase I & II inhibitor
cocktails. The cell lysates were sonicated for 5 sec and concentrated to 30-40
pg protein. k B a degradation was quantified by western blot analysis using an
hcBa (C-21) primary antibody.
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Cytokine-induced IRF-1
CLENDOs of midcycle (passage 5) and early pregnancy (passage 7) were
cultured in 6-well plates to confluence. Prior to cytokine treatment, fresh medium
was applied to the cells. CLENDO cultures were exposed in duplicate to vehicle
(control), TN F (50 ng/ml), TN F + etanercept (10 pg/ml, 30 min pre-treatment),
IFNG (30 ng/ml), IFNG + etanercept, TN F + IFNG, or TNF + IFNG + etanercept
for 90 min or 48 h. After cytokine treatment, the cells were placed on wet ice to
terminate the experiment. Conditioned medium was removed and the cells were
rinsed, lysed, and sonicated as described above. IRF-1 was quantified by
western blot analysis using an IRF-1 (C -20) primary antibody.

Western Blot Analysis
Protein samples (30-40 pg) were subjected to 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAG E) and electrically transferred (75
V for 2 h) to polyvinylidine difluoride (PVD F) membranes. Non-specific binding
was blocked with 5% fat-free milk in TB ST (Tris-Buffered Saline Tween-20: 50
mM Tris HCI pH 7.5, 0.15 M NaCI, 0.05% Tween-20) at room temperature for 1
h. Membranes were probed with primary antibodies I k B oc (C -21) or IRF-1 (C -20)
used at dilutions of 1:1000 with 5% fat-free milk in TBST overnight at 4°C. Four 5
min washes with TBST were performed prior to membrane incubation with an
anti-rabbit peroxidase conjugated IgG used at a 1:2000 dilution for 1 h.
Following four washes with TBST, bound antibody was detected using ECL
detection reagents according to the manufacturer’s instructions. The blots were
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then exposed for 1-10 min using the Kodak Image Station 440 to determine band
intensities., p-actin (1:5000) was used as an internal control to normalize the
data.

IFNG-induced TNF Secretion
CLENDOs of midcycle (passage 6) and early pregnancy (passage 7) were
seeded at a density of 30,000 cells/ml in 24-well plates and grown to confluence.
Prior to cytokine treatment, fresh medium was applied to the cells. EC were
exposed in duplicate to vehicle (control) or IFNG (30 ng/ml or 300 ng/ml) for 24
or 48 h. Upon completion of the time points, conditioned medium was collected
and TNF in the conditioned medium was measured using an enzyme-linked
immunosorbent assay (ELISA).

Cytokine-induced CCL2 Secretion
CLENDOs of midcycle (passage 5) and early pregnancy (passage 7) were
cultured in 6-well plates to confluence. Prior to cytokine treatment, fresh medium
was applied to the cells. CLENDO cultures were exposed in duplicate to vehicle
(control), TNF (50 ng/ml), TN F + etanercept (10 pg/ml, 30 min pre-treatment),
IFNG (30 ng/ml), IFNG + etanercept, TN F + IFNG, or TNF + IFNG + etanercept
for 48 h. Upon termination of the experiments, conditioned medium was
collected. Secretion of CCL2 into culture medium was measured using ELISA.
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Immunoassays
TNF
TNF secretion from CLENDOs was measured using a commercially available
sandwich ELISA specific for bovine TN F (Pierce Biotechnology, Inc.). All
samples were run in duplicate in 96-well plates at a volume of 100 pi conditioned
medium/well. A standard curve was created using recombinant bovine TN F at
concentrations ranging from 39 pg/ml to 2500 pg/ml. The detection limit of the
assay was 29.13 pg/ml and the mean interassay coefficient of variation was 7%.
Results are expressed as pg of TN F per ml of conditioned medium.

CCL2
CCL2 secretion from CLENDOs was measured using a commercially available
sandwich ELISA specific for human CCL2 (R&D Systems). Use of this assay kit
for the measurement of bovine CCL2 has previously been validated [182], and
verified [48, 82], All samples were run in duplicate in 96-well plates at a volume
of 100 pi conditioned medium/well. A standard curve was created using
recombinant human CCL2 at concentrations ranging from 15.6 pg/ml to 1000
pg/ml. The detection limit of the assay was 1.84 pg/ml and the mean interassay
coefficient of variation was 6%. Results are expressed as pg of CCL2 per ml of
conditioned medium.

Cytokine-induced Cell Death
CLENDOs of midcycle (passage 5) and early pregnancy (passage 7) were
seeded at a density of 30,000 cells/ml in 6-well plates and cultured to confluence.
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Along with fresh medium, EC were exposed to vehicle (control), TNF (50 ng/ml),
IFNG (30 ng/ml), or TNF + IFNG for 48 h. For qualitative analysis, numbers of
attached cells in 3 fields of view per well were counted. For quantitative analysis,
cells were removed after 48 h by brief enzymatic treatment using HBSS modified
with 2 mM EDTA and 0.25% trypsin with 0.2% EDTA. The cell suspensions were
spun at 200 x g for 10 min by centrifugation, and the supernatant was removed
using the pour and dab method. The cell pellets were resuspended in 500 pi
HBSS and placed on 12 x 75 mm cell strainer (35 pm) capped polystyrene round
bottom test tubes and centrifuged for 5 min at 200 x g. The strained cells were
fixed using 500 pi of 2% paraformaldehyde (1% final concentration). The cells
were fixed in the dark at 4°C for 45 min. After fixation, the cells were spun down
at 200 x g for 10 min, supernatant removed, and then taken through two PBS
washes. After the washes, the cell pellets were resuspended in 1 ml cold 70%
ethanol and stored at -20°C. Quantification of apoptotic cells was determined
using a modified terminal deoxynucleotide transferase dUTP nick end labeling
(TUNEL) assay, APO-Brdll, according to the manufacturer’s instructions. Briefly,
PRB-1 antibody (anti-Brdll) conjugated to Alexafluor 647 quantified breaks in
cellular DNA, and propidium iodide staining measured DNA content. Cells of the
human lymphoma line, HL-60, supplied by the manufacturer, were used as
positive and negative controls, in which cells were either untreated (negative) or
treated to induce apoptosis (positive). Cell death was measured using a fourcolor, dual-laser FACSCalibur machine. Data were collected using Cellquest and
analyzed using WinMDI software.
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Statistical Analyses
Results were analyzed by two-sample T-test, paired T-test, or by ANOVA using
the general linear model procedure of Minitab (State College, PA) or Systat
(Point Richmond, CA) followed by a Tukey’s multiple comparison test. The
results are expressed as mean + SEM and represent three independent
experiments. A p-value of less than 0.05 was considered significant.

Results
Lectin Binding of CLENDOs
Results of previous studies indicate lectin binding differs among endothelial cells
of the bovine CL depending upon reproductive status and phenotype [172]. The
present experiments were conducted to further assess lectin binding in CLENDO
cultures derived from CL of the estrous cycle and pregnancy (Figs. 4 & 5). Flow
cytometric analysis of FITC-labeled lectins revealed comparable BS-I (Fig. 4) and
ConA (Fig. 5) binding of CLENDOs of the estrous cycle and pregnancy.
Specificity of lectin binding was demonstrated in all cases except one (BS-I on
CLENDOs of pregnancy) by inhibition with the appropriate competing sugar (P <
0.05, Figs. 4 & 5).

Verification of Lectin Binding
Lectin binding of BS-I and ConA was also assessed in BPAECs as a positive
control (Fig. 6) [180, 181], Binding of ConA was greater than BS-I in these
macrovascular endothelial cells (P < 0.05). As above, specificity of lectin binding
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for both BS-I and ConA was demonstrated by displacement with a-D-galactose
and a-D-glucose, respectively (P < 0.05, Fig. 6).

TNF Induces Degradation of licBa
Cultures of CLENDOs exposed to TNF had substantial degradation of licBa (P <
0.05), but there was no difference in Ik B oc degradation attributed to reproductive
status (P > 0.05, Fig. 7).

TNF and IFNG Induce IRF-1 Expression
In cultures of CLENDOs, TN F induced a robust increase in IRF-1 (P < 0.05, Fig.
8) as did IFNG (P < 0.05, Fig. 9). There was no difference in cytokine-induced
IRF-1 expression, however, attributed to reproductive status (P > 0.05, Figs. 8 &
9).

IFNG Induces TNF Secretion by CLENDOs
Conditioned medium from the cultures revealed a dose-dependent increase in
TNF secretion by CLENDOs of the estrous cycle and pregnancy in response to
IFNG stimulation (P < 0.05, Fig. 10). However, there was no difference in TN F
production by CLENDOs attributed to reproductive status (P > 0.05, Fig. 10).

IFNG and TNF Induce CCL2 Secretion by CLENDOs
Conditioned medium from the cultures also revealed an increase in CCL2
secretion by CLENDOs of the estrous cycle and pregnancy in response to TNF
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and IFNG stimulation alone and in combination (P < 0.05, Fig. 11). Again,
however, there was no difference in CCL2 production by CLENDOs based upon
reproductive status (P > 0.05, Fig. 11).

Etanercept Inhibits CCL2 Production and IRF-1 Expression Induced by
TNF, but not IFNG
Etanercept is a synthetic, soluble TN F receptor that functions as a TNF
antagonist [183]. In cultures of CLENDOs, etanercept diminished TNF-induced
CCL2 production by CLENDOs (P < 0.05), but had no effect on IFNG- or TN F +
IFNG-induced CCL2 secretion (P > 0.05, Fig. 11). Reproductive status of the
cow did not alter CLENDO responsiveness (P > 0.05, Fig. 11).

Etanercept also

inhibited IRF-1 expression by TN F and TNF + IFNG following a 90 min treatment
period (P < 0.05, Fig. 12b), but had no effect on IFNG-induced IRF-1 expression
(P > 0.05, Fig. 12b). There was no difference in etanercept inhibition of IRF-1 in
CLENDOs attributed to reproductive status at 90 min (P > 0.05, Fig. 12b).
However, etanercept failed to inhibit cytokine-induced IRF-1 expression following
a 48 h treatment period (Fig. 12d), and IRF-1 expression was greater in
CLENDOs of the estrous cycle (P < 0.05, Fig. 12d).

Cytotoxic Effect of TNF on CLENDOs of the Estrous Cycle
The cytokines TN F and TNF + IFNG are cytotoxic to CLENDOs of pregnancy
[139]. In the current study, cytokines had a similar effect on CLENDOs of the
estrous cycle. That is, IFNG alone failed to induce cell death, but TNF and TN F
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+ IFNG induced death in approximately 30% and 10% of the cells based upon
visual observation (Fig. 13) and quantification of APO-BrdU labeling by flow
cytometric analysis (Fig. 15), respectively.
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Figure 4. BS-I lectin binding of CLENDOs of the estrous cycle and pregnancy as
determined by flow cytometric analysis.
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Representative flow cytometric
histogram of BS-I binding in
CLENDOs (Fig. 4a). A right shift
along the x-axis indicates
increased lectin binding of FITClabeled BS-I. Addition of the
competing sugar, a-D-galactose,
displaced lectin binding, yielding
a shift equivalent to controls.
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binding was increased, but
comparable in CLENDOs of
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pregnancy (P > 0.05). Different
letters denote significant
differences in lectin binding
among the treatments and cell
types (P < 0.05).
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Figure 5. ConA lectin binding of CLENDOs of the estrous cycle and pregnancy as
determined by flow cytometric analysis.
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Figure 6. Lectin binding of BPAECs as a positive control for lectin binding of CLENDOs.
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Figure 7. TNF-induced Ik Bcc degradation in CLENDOs of the estrous cycle and
pregnancy.
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Ik B oc degradation in CLENDOs. Within 15 minutes of exposure to TNF, CLENDOs
exhibited a 5-fold decrease in Ik B cc (P < 0.05). CLENDOs of midcycle did not differ from
CLENDOs of pregnancy with respect to the effect of TNF (P > 0.05). Bars represent
relative intensity of hcBa normalized to p-actin + SEM (n=3 experiments). Different
letters denote significant differences in kB a degradation among the treatments and cell
types (P < 0.05).
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Figure 8. TNF-induced IRF-1 expression in CLENDOs of the estrous cycle and
pregnancy.
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Representative western blot (Fig. 8a) and bar graph (Fig. 8b) depicting TNF-induced
IRF-1 expression in CLENDOs. Within 90 minutes of exposure to TNF, CLENDOs
exhibited a 4-fold increase in IRF-1 expression (P < 0.05). CLENDOs of midcycle did
not differ from CLENDOs of pregnancy with respect to the effect of TNF (P > 0.05). Bars
represent relative intensity of IRF-1 normalized to p-actin + SEM (n=3 experiments).
Different letters denote significant differences in IRF-1 expression among the treatments
and cell types (P < 0.05).
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Figure 9. IFNG-induced IRF-1 expression in CLENDOs of the estrous cycle and
pregnancy.
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Representative western blot (Fig. 9a) and bar graph (Fig. 9b) depicting IFNG-induced
IRF-1 expression in CLENDOs. Within 90 minutes of exposure to IFNG, CLENDOs
exhibited a 14-fold increase in IRF-1 expression (P < 0.05). CLENDOs of midcycle did
not differ from CLENDOs of pregnancy with respect to the effect of IFNG (P > 0.05).
Bars represent relative intensity of IRF-1 normalized to p-actin + SEM (n=3
experiments). Different letters denote significant differences in IRF-1 expression among
the treatments and cell types (P < 0.05).
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Figure 10. IFNG-induced TNF secretion by CLENDOs of the estrous cycle and
pregnancy.
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TNF secretion by CLENDOs of the estrous cycle and pregnancy in culture over a 48 h
treatment period as determined by ELISA of conditioned culture medium. Response to
IFNG at 30 ng/ml and 300 ng/ml is shown. Overall response to IFNG did not differ
between CLENDOs of the estrous cycle and pregnancy (P > 0.05). Bars represent
mean protein secretion + SEM (n=3 experiments). Different letters denote differences in
TNF protein secretion among the treatments and cell types (P < 0.05).

58

R eproduced with perm ission o f the copyright owner. F urther reproduction prohibited w itho ut perm ission.

Figure 11. Cytokine-induced CCL2 secretion by CLENDOs of the estrous cycle and
pregnancy.
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CCL2 secretion by CLENDOs of the estrous cycle and pregnancy in culture over a 48 h
treatment period as determined by ELISA of conditioned culture medium. Responses to
the cytokines TNF and IFNG, and the TNF antagonist, etanercept, are shown. Overall
response to cytokines did not differ between CLENDOs of the estrous cycle and
pregnancy (P > 0.05). Bars represent mean protein secretion + SEM (n=3 experiments).
Different letters denote differences in CCL2 protein secretion among the treatments and
cell types (P < 0.05).
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Figure 12. Effect of etanercept on cytokine-induced IRF-1 expression in CLENDOs of
the estrous cycle versus pregnancy.
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Representative western blot (Fig. 12a) and bar graph (Fig. 12b) depicting cytokineinduced IRF-1 expression in CLENDOs of the estrous cycle and pregnancy over a 90 min
treatment period. Responses to the cytokines TNF and IFNG, and the TNF antagonist,
etanercept, are shown. Overall response to cytokines did not differ between CLENDOs of
the estrous cycle and pregnancy (P > 0.05). Bars represent relative intensity of IRF-1
normalized to p-actin + SEM (n=3 experiments). Different letters denote significant
differences in IRF-1 expression among the treatments and cell types (P < 0.05).
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Figure 12c.
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Representative western blot (Fig. 12c) and bar graph (Fig. 12d) depicting cytokineinduced IRF-1 expression in CLENDOs of the estrous cycle and pregnancy over a 48 h
treatment period. Responses to the cytokines TNF and IFNG, and the TNF antagonist,
etanercept, are shown. Overall response to cytokines differed between CLENDOs of the
estrous cycle and pregnancy (P < 0.05). Bars represent relative intensity of IRF-1
normalized to p-actin + SEM (n=3 experiments). Different letters denote significant
differences in IRF-1 expression among the treatments and cell types (P < 0.05).
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Figure 13. Qualitative cytokine-induced cell death in CLENDOs of the estrous cycle.
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Cytokine-induced cell death in CLENDOs of the estrous cycle over a 48 h treatment
period. Responses to the cytokines TNF and IFNG are shown. IFNG failed to induce
cell death in CLENDOs from midcycle CL. Conversely, TNF and TNF + IFNG resulted in
approximately 60% death (P < 0.05). Bars represent percentage of viable cells + SEM
(n=3 experiments). Different letters denote differences in cell death among the
treatment groups (P < 0.05).
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Figure 14. Cytokine-induced cell death visual observations.
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Representative phase-contrast photomicrographs (25x magnification) of midcycle
CLENDO cultures following 48 h of the indicated treatments (Fig. 14). Yellow boxes
highlight areas affected by the corresponding treatments. Control cells display
cobblestone morphology, with the monolayer intact (Fig. 14a). IFNG-treated cells
display large, flattened, senescent-like cells between areas of intact monolayer (Fig.
14b). TNF treatment resulted in characteristic signs of death, including the obvious
reduction in attached cells (Fig. 14c). Finally, TNF + IFNG treatment resulted in similar
effects seen with TNF alone, with fewer cells attached to the cultureware (Fig. 14d).
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Figure 15. Quantitative cytokine-induced cell death in CLENDOs of the estrous cycle.
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Cytokine-induced cell death in CLENDOs of the estrous cycle over a 48 h treatment
period. Responses to the cytokines TNF and IFNG are shown as representative flow
cytometric density plots of TUNEL labeling in CLENDOs (Fig. 15a). A shift in the cell
population to the right indicates increased TUNEL label/apoptosis. The percentage of
apoptotic cells was extrapolated and is represented as bars + SEM, n=3 experiments (Fig.
15b). IFNG failed to induce cell death, but TNF and TNF + IFNG resulted in approximately
15% and 10% death, respectively. However, there was no difference in cell death among
the treatment groups (P > 0.05).
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Discussion
In the present study, structural and functional characteristics of CLENDOs
of the estrous cycle and pregnancy were compared to elucidate the influence of
reproductive status on the diversity of the luteal micro vasculature. W e
determined CLENDOs of the estrous cycle and pregnancy have similar
properties of lectin binding and responsiveness to the cytokines TN F and IFNG.
Specifically, the extent of BS-I and ConA binding was comparable in CLENDOs
of the estrous cycle and pregnancy. TN F induction of k B a degradation, IRF-1
production, and cell death were likewise similar in CLENDOs of the estrous cycle
and pregnancy. IFNG stimulated IRF-1 production and, in combination with TNF,
induced apoptosis in CLENDOs of the estrous cycle and pregnancy. In addition,
these studies provide the first convincing evidence that CLENDOs are a source
of TNF production, but this phenomenon was not influenced by reproductive
status of the cow. Collectively, these results indicate that microvascular
endothelial cells of the bovine CL do not change morphologically or functionally
throughout the estrous cycle and early pregnancy. These findings are significant
because previous studies have reported or alluded to physiological distinctions
between the CL of the estrous cycle and of pregnancy.
Binding of the lectins BS-I and ConA were detected by flow cytometric
analysis of CLENDOs of the estrous cycle and pregnancy and revealed relatively
equal mean fluorescence intensities. Determining lectin binding properties of
these cell types is important because BS-I is an accepted endothelial cell marker
which has been used extensively in magnetic bead isolation of CLENDOs for in
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vitro experimentation [62, 167, 168, 170, 171]. Lectin binding to endothelial cells,
however, is species, age, organ, and vascular bed specific [173]. BS-I is
considered a constitutive endothelial cell marker throughout the developmental
stages of the corpus luteum [20], but others indicate that BS-I expression is more
ubiquitous, with BS-I binding found in an array of bovine cell types including
epithelial cells, endothelial cells, smooth muscle cells, thymocytes, and
fibroblasts [184], These observations indicate BS-I potentially binds other cell
types within the CL and not exclusively endothelial cells, as previously suggested
[173]. Thus, magnetic bead isolation of CLENDOs based upon BS-I binding
might not be an ideal approach for obtaining pure cultures of CLENDOs, as it has
the potential to introduce other, contaminating cell types into the culture.
In one previous study, Plendl et al. (1996) reported differences in lectin
binding between CLENDOs of the estrous cycle and pregnancy and among
CLENDO phenotypes [172]. Two distinct cell types derived from the estrous
cycle and pregnancy were described: cobblestone and arcuate morphology.
Using flow cytometric analysis, the authors found BS-I binding to both
cobblestone and arcuate CLENDOs of pregnancy upregulated (~2-fold) as
compared to the same cell types of the estrous cycle. Furthermore, BS-I binding
to cobblestone endothelial cells is approximately 3-fold greater than arcuate
endothelial cells from CL of pregnancy. In contrast, binding of BS-I to the
cobblestone cell type in CL of the estrous cycle is approximately 1.5-fold less
than the arcuate phenotype [172]. Collectively, these results indicate differences
in lectin binding based on reproductive status and phenotype. In the current
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study, we found no difference in lectin binding due to reproductive status. The
disparity between our results and those of Plendl and co-workers (1996) might be
due to differences in experimental methods. For instance, the cell types utilized
in the current investigation were both cobblestone and arcuate morphology, and
presumably constitute the predominant phenotypes of endothelial cells within the
bovine CL. Plendl et al. (1996) used specific phenotypes as previously described
by Spanel-Borowski and van der Bosch (1990) [70], If specific morphologic
phenotypes have indeed higher lectin binding than others as Plendl et al. (1996)
suggest, then a mixture of the predominant phenotypes might mask substantial
differences in lectin binding for a particular cell type. Further quantitative
analysis of lectin binding will be needed to clarify specificity in CLENDOs, not
only because of the emerging use of lectins in magnetic bead isolation, but also
because of their role in cell-cell interactions. Hyperglycosylation or upregulation
of lectin binding on endothelial cells has emerged as a mechanism of cell
migration in bovine aortic endothelial cells [173], Migrating endothelial cells
precede proliferation of endothelial cells during angiogenesis. Upregulation of
lectin binding is considered important in these cell-cell interactions, particularly
with other endothelial cells or immune cells, especially in the context of
inflammatory processes [20, 173].
BPAECs were used in the current experiments as a positive control for
BS-I and ConA binding, as documented by others [180, 181]. The BPAECs
display higher mean fluorescence intensity than CLENDOs. The difference in
lectin binding could be due to innate differences in the macrovasculature versus
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microvasculature, or a difference in cell numbers used in the experiments. The
BPAECs were analyzed for lectin binding at a concentration of -2 0 0 ,0 0 0 cells/ml,
whereas the CLENDOs were analyzed at -4 0 0 ,0 0 0 cells/ml. Considering the
same concentration of FITC-labeled lectin was used for each cell type, the
BPAECs could have been oversaturated with FITC-labeled lectin, revealing a
higher binding capacity. Additionally, ConA binding was higher than BS-I in
BPAECs. This is not unexpected, as there is documentation alluding to a higher
binding capacity for ConA compared to BS-I in BPAECs, based upon lectin
affinity chromatography [180].
The endothelium is a major target for cytokines in most tissues and is
pivotal to immune processes, particularly inflammation. Endothelial cells serve
as part of the barrier between the blood stream and the tissues, determining the
traffic and action of cells and molecules within the body [81]. Knowing that large
numbers of endothelial cells compose the CL [17], endothelial cells and their
responsiveness to cytokines are reasoned to be important in luteal regression.
Here, intracellular signaling pathways of CLENDOs induced in response to TN F
and IFNG stimulation were investigated. Nuclear factor kappa B (NF- k B)
activation, via Ik Boc degradation, and IRF-1 were induced equally in CLENDOs of
the estrous cycle and pregnancy. Others have noted similar signaling events of
TNF and IFNG in bovine steroidogenic cells [112], but this is the first study, to our
knowledge, investigating these aspects of cytokine signaling in bovine
CLENDOs.
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Activation of the NF- k B signaling pathway stimulates the production of
proinflammatory mediators, such as TN F and CCL2 [123,185], possibly
contributing to immune mediated events during luteal regression. In the current
study, TNF-induced k B a degradation indicates NF- k B activation in both cell
types, revealing that proinflammatory pathways are equally inducible during the
estrous cycle and pregnancy. Likewise, TNF-induced IRF-1 expression further
validates NF- k B activation in both cell types, as IRF-1 induction is mediated by
NF-k B [96]. IRF-1 expression is also mediated by signal transducers and
activators of transcription (Stat). Therefore, IFNG, which signals through the
Janus kinase (Jak)-Stat pathway, is a potent inducer of IRF-1 [84]. In the current
study, CLENDOs of the estrous cycle and pregnancy equally expressed IRF-1
following stimulation with IFNG. IRF-1 regulates the transcription of IFNGresponsive genes, such as MHC expression [103]. In fact, IFNG induces the
expression of MHC class II molecules on bovine luteal steroidogenic cells [109]
and CLENDOs [110]. Also, IFNG increases the expression of TNF receptors on
the surface of cells [93, 94], The role of IRF-1 in these actions of IFNG is not
known, but based on our observations and those of Suter and co-workers (2001)
[112], IFNG and/or TNF activation of IRF-1 might induce these effects in the CL,
thus contributing to immune-mediated events during luteal regression.
One culminating effect of cytokines in CLENDOs is the onset of apoptosis.
Apoptotic death in CLENDOs of pregnancy induced by T N F alone and in
combination with IFNG has been documented [139], An incidence of 30% death
and 50% death was reported following TNF and TNF + IFNG treatment,
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respectively [139]. In the present study, cytokine-induced apoptosis of
CLENDOs of the estrous cycle was measured both qualitatively and
quantitatively. Our visual observations were similar to those reported by Pru and
co-workers (2003) [139] for CLENDOs of pregnancy in that TN F resulted in
significant death (-6 0 % ). However, TN F + IFNG did not increase the incidence
of death. Instead, IFNG provoked a morphological change in the cells, with little
to no death, and more enlarged, senescent-like cells. Similar observations
following IFNG treatment have been reported by others [72, 73]. The
combination of a morphological change in the cells along with the appearance of
senescent-like cells indicates that IFNG may have an overall negative influence
on CLENDOs without resulting in apoptosis. IFNG could possibly alter the
metabolic activity of the cells, particularly decreasing it, resulting in a cytostatic
culture. This would explain the anti-proliferative nature of the cells and the lack
of death.
Quantitative analysis of cytokine-induced death by TUNEL assay and flow
cytometric analysis yielded results of less cell death than our visual observations.
TNF induced approximately 15% death, while TN F + IFNG induced
approximately 10% death. TUNEL staining was used to identify strand breaks in
DNA, the final step in the apoptotic process. Cells undergoing apoptosis (i.e.
increased caspase production) but not to the point of DNA degradation, would
not be detected by the TUNEL assay. Thus, our cytometric results are a
conservative measure of cell death as compared to the more subjective measure
of visual assessment. Moreover, flow cytometric analysis of TUNEL staining

70

R eproduced with perm ission o f the copyright owner. F urther reproduction prohibited w itho ut perm ission.

eliminates any subjective bias of visual counting of TUNEL-positive dead cells.
Given these considerations, the conservative estimate of cytokine-induced
apoptosis of CLENDOs in the current study is not surprising.
Understanding the mechanisms of TNF receptor signaling could be key to
understanding the apoptotic actions of TN F and TNF + IFNG on CLENDOs.
TNF, via TNF receptor 1, signals through both pro- and anti-apoptotic pathways
[121]. Ligand binding induces the activation of death domain associated
proteins, such as caspases, while also inducing the activation of NF- k Bassociated anti-apoptotic proteins such as cellular FLICE-like inhibitory protein
(cFLIP), B-cell leukemia/lymphoma 2 (Bcl-2), and cellular inhibitor of apoptosis
protein-1 (clAP-1) [121]. Inhibition of NF- k B activity by proteins such as IRF-1
leads to increased cellular susceptibility to TNF-induced apoptosis [121]. TNF
and IFNG independently and synergistically promote the expression of IRF-1
[152]. IRF-1 inhibits NF- k B mediated activation of cell survival signals through
modulation of NF- k B transcriptional activity [106]. Therefore, IRF-1 induction by
TNF and IFNG could inhibit the anti-apoptotic NF- k B pathway, resulting in cell
death/apoptosis. In the present study, TN F and IFNG alone and in combination
induced IRF-1 expression in CLENDOs, but there was no effect attributable to
reproductive status. The ability of TN F and IFNG to activate signaling pathways
in CLENDOs of the estrous cycle and pregnancy that result in IRF-1 expression
could explain the noted increase in death seen with TNF + IFNG as compared to
TNF alone by Pru and co-workers (2003) [139]. With TN F alone, both pro- and
anti-apoptotic pathways become activated, resulting in some limited cell death.
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Conversely, with TNF + IFNG, the pro-apoptotic pathway prevails. The
synergistic increase in IRF-1 expression decreases the activation of the antiapoptotic NF-k B pathway, thereby inhibiting production of anti-apoptotic proteins,
and increasing the extent of cell death. Measuring the expression of antiapoptotic proteins under similar cytokine treatments could provide insight into this
paradigm.
The cellular source(s) of TNF within the CL has been debated for a
number of years. Hehnke-Vagnoni and co-workers (1995) localized TN F to
endothelial cells of the porcine CL, stating that macrophages are rarely evident
and not associated with TN F production [126]. In contrast, Zhao and co-workers
(1998) identified macrophages as the major source of TN F within the porcine CL,
finding that endothelial cells consistently lacked TN F staining [127]. For both
studies, the basis of TN F assessment utilized immunohistochemistry and/or TNF
bioassay. Neither study measured TNF production by quantitative immunoassay
using purified cell preparations. The present study used a bovine TNF ELISA to
determine TN F production by CLENDOs of the estrous cycle and pregnancy.
Under the stimulation of IFNG, both cell types dose-dependently produced an
equivalent amount of TNF. This study is the first to quantify TN F production by
endothelial cells of the bovine CL. The implications of this production include the
possible autocrine effect TN F may have on CLENDOs to influence cellular
signaling and apoptosis. TN F receptors are localized to small luteal cells (small
steroidogenic and endothelial cells) of the CL [130, 133] indicating that
endothelial cells could produce TN F under IFNG stimulation and respond to TNF
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in an autocrine manner. These possibilities raise the question of whether or not
some actions of IFNG are mediated through TNF pathways. W e assessed this
possibility using a TN F antagonist, the synthetic soluble TN F receptor,
etanercept [183].
Cytokine-induced CCL2 production by CLENDOs of pregnancy has been
previously documented by our laboratory [48, 82], W e have now determined that
cytokine-induced CCL2 production also occurs in CLENDOs of the estrous cycle,
and thus, is not affected by reproductive status. Etanercept did not affect IFNGinduced CCL2 production, suggesting that IFNG-induced production of CCL2 is
not via an autocrine effect of TNF. Consistent with the results seen for CCL2,
etanercept also did not alter IFNG-induced IRF-1 expression. The efficacy and
specificity of etanercept was demonstrated by its ability to inhibit TNF-induced
CCL2 production and IRF-1 expression. Together, these results indicate the
actions of IFNG are not mediated through TN F pathways. However, the ability of
etanercept to prevent TNF-induced signaling has important experimental
implications for luteal regression. Future in vivo work, such as treating cows with
etanercept, could be conducted to determine the effect of TNF inhibition during
natural luteal regression.
Another interesting finding of the etanercept experiments was the outcome
observed following treatment exposure time. Following a 90 min treatment
period, etanercept inhibited TNF-induced IRF-1 expression, and there was no
difference in IRF-1 expression due to reproductive status of the cow. However,
following a 48 h treatment period, there was no significant inhibition of TN F-
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induced IRF-1 expression, and IRF-1 expression was greater in CLENDOs of the
estrous cycle. Suter et al. (2001), using CLENDOs of pregnancy, did not detect
TNF-induced IRF-1 expression at 24 or 48 h [112]. In contrast, not only was
TNF-induced IRF-1 detected after 48 h in the current study, but there was an
overall increase in IRF-1 expression due to reproductive status, with a trend
toward greater IRF-1 expression in CLENDOs of the estrous cycle. It appears
CLENDOs of the estrous cycle respond more readily to cytokines over an
extended exposure period than CLENDOs of pregnancy. The reason for this is
unknown, but perhaps CLENDOs of pregnancy establish mechanisms to tolerate
systemic levels of cytokines and immune events associated with implantation
and pregnancy.
The current study compared structural and functional characteristics of
CLENDOs of the estrous cycle and CLENDOs of pregnancy. Our results indicate
luteal microvascular endothelial cells do not drastically change, structurally or
functionally, as the cells transition from the estrous cycle into pregnancy.
However, initial disparities in the response of CLENDOs of the estrous cycle
versus pregnancy regarding TN F- and TN F + IFNG-induced apoptosis could
indicate potential differences in the susceptibility of these cells to mechanisms of
apoptosis. Such mechanisms have important implications in understanding the
adaptable existence of the luteal microvasculature, and also in comprehending
the basic processes of angiogenesis and angioregression. These observations
are significant not only to reproduction and fertility, but also to our understanding
of angiogenesis and angioregression for cancer research.
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